Nanjing Zaiming Pharmaceutical Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Shandong Luye Pharmaceutical Co. Ltd. has divulged tachykinin NK3 receptor antagonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), depression, pain, obesity, cognitive disorders, inflammatory disorders, psychosis and urinary incontinence, among others.
Nanjing Mingde New Drug Research Co. Ltd. has designed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety via a linker for the treatment of cancer.
Scientists at Oncopia Therapeutics Inc. (dba SK Life Science Labs) and The University of Michigan have synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon E3 ubiquitin ligase-binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β)-targeting agent through a linker.
Kangbaida (Sichuan) Biotechnology Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) ligand coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety through a linker.
Haihe Biopharma Co. Ltd. has published work on the discovery of novel ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) inhibitors being developed for the treatment of cancer.
Researchers from Shanghai Institute of Biological Products Co. Ltd. published details on the development and preclinical characterization of novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, referred to as tandem antigen-binding fragment 002 (TFAB-002).
Protein homeostasis is disrupted in response to an uncontrolled stress condition, a hallmark of many diseases, such as cataracts. Lens protein accumulation and aggregates are a cause of cataract development.
Researchers from Nanjing First Hospital reported that glutamine-fructose-6-phosphate transaminase 2 (GFPT2) may be considered a diagnostic and prognostic marker of mesothelioma.
Researchers from Proqr Therapeutics NV recently presented preclinical data on AX-0810, a single-stranded RNA editing oligonucleotide (EON) targeting RNA coding for NTCP cotransporter
RSS
